

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

APOTEX, INC.,

Petitioner,

v.

CELGENE CORPORATION,

Patent Owner.

---

Case IPR2023-00512

Patent 8,846,628

---

**DECLARATION OF AMY K. WIGMORE IN SUPPORT OF  
UNOPPOSED MOTION FOR ADMISSION *PRO HAC VICE***

CELGENE 2154  
APOTEX v. CELGENE  
IPR2023-00512

I, Amy K. Wigmore, declare as follows:

1. I obtained a B.A. from the University of Massachusetts in 1992 and a J.D. from the Harvard Law School in 1995.

2. I am currently a partner in the law firm of Wilmer Cutler Pickering Hale and Dorr LLP. I was admitted to the Massachusetts Bar in January of 1996 and the District of Columbia Bar in December of 1996. I have been practicing law for over 20 years. For more than 15 years, my practice has focused primarily on patent litigation. Over the course of my career, I have been counsel in dozens of patent litigations.

3. I am a member in good standing of the Bars of the Commonwealth of Massachusetts and District of Columbia. I am admitted to practice before the U.S. District Courts for the District of Columbia, District of Colorado, and District of Massachusetts. I am also admitted to practice before the U.S. Court of Appeals for the Federal Circuit, the D.C. Circuit, and the Sixth Circuit, as well as the Supreme Court of the United States. I am also admitted to practice before the District of Columbia Court of Appeal, the Supreme Judicial Court of Massachusetts, and the United States Court of Appeals for Veterans Claims.

4. My Massachusetts Bar membership number is 629275. My District of Columbia Bar membership number is 453164.

5. I have appeared *pro hac vice* before the Office in the following proceedings: *Apotex Inc. v. OSI Pharmaceuticals Inc.*, IPR2016-01284 (*pro hac vice* granted); *OSI Pharmaceuticals, LLC v. Arch Development Corp.*, IPR2016-01034 (*pro hac vice* granted); *Boehringer Ingelheim GmbH v. AbbVie Biotechnology Ltd.*, IPR2016-00408 (*pro hac vice* granted); *Boehringer Ingelheim GmbH v. AbbVie Biotechnology Ltd.*, IPR2016-00409 (*pro hac vice* granted); *Coherus BioSciences Inc. v. AbbVie Biotechnology Ltd.*, IPR2016-00188 (*pro hac vice* granted); *Coherus BioSciences Inc. v. AbbVie Biotechnology Ltd.*, IPR2016-00189 (*pro hac vice* granted); *Coherus BioSciences Inc. v. AbbVie Biotechnology Ltd.*, IPR2016-00172 (*pro hac vice* granted).

6. I have an established familiarity with the subject matter of U.S. Patent No. 8,846,628 (the '628 patent), the '628 patent's file history, and the prior art at issue in this proceeding. I am familiar with pharmaceutical technologies as a result of participation as counsel in related district court litigations on the '628 patent as well as many prior pharmaceutical-related intellectual property cases on behalf of Patent Owners and Bristol-Myers Squibb Co. I have also recently represented other pharmaceutical companies, including, among others, Exelixis, Inc., ModernaTX, Inc., and ModernaUS, Inc. in intellectual property matters before federal courts, including matters involving formulation technology.

7. I have never been suspended or disbarred from practice before any court or administrative body.

8. I have never had a court or administrative body deny my application for admission to practice.

9. I have never had any sanctions or contempt citations imposed on me by any court or administrative body.

10. I attest to each of the listed items required by the Order – Notice of Filing Date Accorded to Petition And Time For Filing Patent Owner Preliminary Response in IPR2023-00512.


11. I have read and will comply with Office Patent Trial Practice Guide and the Board’s Rules of Practice for Trials, as set forth in 37 C.F.R. Part 42.

12. I agree to be subject to the United States Patent and Trademark Office Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq. and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like are punishable by fine, imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Dated: October 31, 2023

Respectfully submitted,

  
Amy K. Wigmore  
WILMER CUTLER PICKERING  
HALE AND DORR LLP  
2100 Pennsylvania Ave NW  
Washington, DC, 20037  
Amy.Wigmore@wilmerhale.com  
Tel.: 202-663-6096  
Fax: 202-663-6363